Nicaise Claude 4
4 · Sarepta Therapeutics, Inc. · Filed Mar 13, 2025
Insider Transaction Report
Form 4
Nicaise Claude
Director
Transactions
- Exercise/Conversion
Common Stock
2025-03-12$25.18/sh+9,746$245,404→ 30,303 total - Sale
Common Stock
2025-03-12$99.64/sh−2,491$248,203→ 27,812 total - Exercise/Conversion
Stock Options (right to buy)
2025-03-12−9,746→ 0 totalExercise: $25.18From: 2016-06-02Exp: 2025-06-02→ Common Stock (9,746 underlying)
Footnotes (2)
- [F1]The shares were sold to cover the exercise price relating to the exercise of stock options to purchase shares, which are scheduled to expire in 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.64 and $99.87, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.